Add to ORKGHuman blood and blood products is the source of a wide range of medicinal products used for the treatment and prevention of a variety of injuries and disease. Despite stringent routine measures and filters employed, residual pathogen infectivity remains an important challenge in the field of blood transfusion. In this article various measures and technologies that can be applied in order to reduce the residual risk are reviewed
Millions of patients in the UK benefit from the use of both plasma derivatives and blood components ...
There are continuing concerns over the safety of the nation’s and the world’s blood supply. The allo...
In line with current microbial risk reduction efforts, pathogen inactivation (PI) technologies for b...
The pathogen safety of blood/plasma-derived products has historically been a subject of significant ...
AbstractThe pathogen safety of blood/plasma-derived products has historically been a subject of sign...
Substantial improvements in the safety of blood and plasma products for the management of bleeding d...
Although existing clinical evidence shows that the transfusion of blood components is becoming incre...
Safe transfusion therapy is a basic requirement for advanced medical care. In order to establish pri...
Pathogen inactivation of blood products represents a global and major paradigm shift in transfusion ...
Some bacterial, parasitic, fungal and viral agents can be transferred by blood transfusion. A number...
The spectrum of adverse reactions to blood product transfusion ranges from a benign clinical course ...
As a result of immunological and nucleic-acid screening of plasma donations for transfusion-transmis...
Although existing clinical evidence shows that the transfusion of blood components is becoming incre...
Transfusion has become extremely safe but can still be associated with adverse reactions. Some adver...
Blood transfusion is an important aspect of medicine and patient safety plays a very important role....
Millions of patients in the UK benefit from the use of both plasma derivatives and blood components ...
There are continuing concerns over the safety of the nation’s and the world’s blood supply. The allo...
In line with current microbial risk reduction efforts, pathogen inactivation (PI) technologies for b...
The pathogen safety of blood/plasma-derived products has historically been a subject of significant ...
AbstractThe pathogen safety of blood/plasma-derived products has historically been a subject of sign...
Substantial improvements in the safety of blood and plasma products for the management of bleeding d...
Although existing clinical evidence shows that the transfusion of blood components is becoming incre...
Safe transfusion therapy is a basic requirement for advanced medical care. In order to establish pri...
Pathogen inactivation of blood products represents a global and major paradigm shift in transfusion ...
Some bacterial, parasitic, fungal and viral agents can be transferred by blood transfusion. A number...
The spectrum of adverse reactions to blood product transfusion ranges from a benign clinical course ...
As a result of immunological and nucleic-acid screening of plasma donations for transfusion-transmis...
Although existing clinical evidence shows that the transfusion of blood components is becoming incre...
Transfusion has become extremely safe but can still be associated with adverse reactions. Some adver...
Blood transfusion is an important aspect of medicine and patient safety plays a very important role....
Millions of patients in the UK benefit from the use of both plasma derivatives and blood components ...
There are continuing concerns over the safety of the nation’s and the world’s blood supply. The allo...
In line with current microbial risk reduction efforts, pathogen inactivation (PI) technologies for b...